Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B

World Journal of Gastroenterology

Volumn 21, Issue 7, 2015, Pages 2089-2095

  Tan, You Wen ^a   Ye, Yun ^a   Ge, Guo Hong ^a   Zhao, Wei ^b   Gan, Jian He ^c   Zhao, Yun ^d   Niu, Zhi Lin ^e   Zhang, Dong Jun ^e   Chen, Li ^a   Yu, Xue Jun ^a   Yang, Li Jun ^a  

^a JIANGSU UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d YANGZHOU UNIVERSITY   (China)

^e NANTONG MEDICAL COLLEGE   (China)

Author keywords

Chronic hepatitis B; Lamivudine; Mutation; Tyrosine Methionine aspartic acid aspartic acid; Virological breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ASPARTIC ACID; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHIONINE; TYROSINE; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHRONIC HEPATITIS; COMPARATIVE STUDY; DELTA AGENT HEPATITIS; DISEASE COURSE; DRUG EFFICACY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; ANTIVIRAL RESISTANCE; BLOOD; CHINA; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; MUTATION; PROTEIN MOTIF; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; AMINO ACID MOTIFS; ANTIVIRAL AGENTS; BIOMARKERS; CHINA; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922722052     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i7.2089     Document Type: Article

References (28)

1. Evans AA, London WT, Gish RG, Cohen C, Block TM. Chronic HBV infection outside treatment guidelines: is treatment needed? Antivir Ther 2013; 18: 229-235 [PMID: 22914436 DOI: 10.3851/IMP2325]
2. Hösel M, Lucifora J, Michler T, Holz G, Gruffaz M, Stahnke S, Zoulim F, Durantel D, Heikenwalder M, Nierhoff D, Millet R, Salvetti A, Protzer U, Büning H. Hepatitis B virus infection enhances susceptibility toward adeno-associated viral vector transduction in vitro and in vivo. Hepatology 2014; 59: 2110-2120 [PMID: 24425003 DOI: 10.1002/hep.26990]
3. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717 [PMID: 8781348]
4. Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006; 21: 1769-1771 [PMID: 17074012]
5. Yan MH, Zhang C, Ling Q, Zhou RF. [Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B]. Zhonghua Ganzangbing Zazhi 2003; 11 : 430-431 [PMID: 12890351]
6. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37: 259-265 [PMID: 12127432]
7. Shin YM, Heo J, Kim GH, Kang DH, Song GA, Cho M, Yang US, Kim CM, Park HK, Jang HJ. [Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients]. Taehan Kan Hakhoe Chi 2003; 9: 1-9 [PMID: 12657823]
8. Kobayashi S. Clinical characteristics of asymptomatic hepatitis B virus carriers with YMDD mutant not treated with lamivudine. Kurume Med J 2003; 50: 87-90 [PMID: 14768470]
9. Heo J, Cho M, Kim HH, Shin YM, Jang HJ, Park HK, Kim CM, Kim GH, Kang DH, Song GA, Yang US. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 2004; 19: 541-546 [PMID: 15308845]
10. Horgan M, Brannigan E, Crowley B, Levis J, Fanning LJ. Hepatitis B genotype and YMDD profiles in an untreated Irish population. J Clin Virol 2006; 35: 203-204 [PMID: 16213785]
11. Min XC, Miao XH, Zhao SM, Zhao KK, Yang DG. [The spontaneous YMDD mutation rate in chronic hepatitis B patients]. Zhonghua Ganzangbing Zazhi 2009; 17 : 887-890 [PMID: 20038327]
12. Lee SH, Kim HS, Byun IS, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol 2012; 84: 217-222 [PMID: 22170540 DOI: 10.1002/jmv.23191]
13. Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, Tang H. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. Antivir Ther 2012; 17: 973-979 [PMID: 22728692 DOI: 10.3851/IMP2190]
14. Tan YW, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis 2012; 16: 250-255 [PMID: 22729192]
15. Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19: 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665]
16. Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19 : 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278]
17. Yang J, Chen X, Zhang H, Chen G. HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma. J Med Virol 2014; 86: 913-917 [PMID: 24615989 DOI: 10.1002/jmv.23895]
18. Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19: 3861-3865 [PMID: 23840126 DOI: 10.3748/wjg.v19.i24.3861]
19. Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. PLoS One 2012; 7: e32789 [PMID: 22479339 DOI: 10.1371/journal.pone.0032789]
20. Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stöckl E. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J Clin Microbiol 2001; 39: 1972-1974 [PMID: 11326026]
21. Ducancelle A, Servant-Delmas A, Beuvelet T, Balan V, Pivert A, Maniez M, Laperche S, Lunel-Fabiani F. [Results of a novel real-time PCR, sequence analysis, Inno-LiPA line probe assays in the detection of hepatitis B virus G1896A precore mutation in French blood donors]. Pathol Biol (Paris) 2011; 59 : e21-e27 [PMID: 20843617 DOI: 10.1016/j.patbio.2010.07.014]
22. Da Silva LC, da Fonseca LE, Carrilho FJ, Alves VA, Sitnik R, Pinho JR. Predictive factors for response to lamivudine in chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2000; 42: 189-196 [PMID: 10968881]
23. Aʇca H, Sayiner AA, Sengönül A, Simşek I, Akarsu M. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations]. Mikrobiyol Bul 2011; 45: 664-676 [PMID: 22090297]
24. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-896 [PMID: 10051494]
25. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157 [PMID: 7475613]
26. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661 [PMID: 7477217]
27. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396-397 [PMID: 7845151]
28. Jung MC, Zachoval R, Sackmann M. [Therapy of chronic hepatitis B virus infection with the nucleoside analog lamivudine]. Z Gastroenterol 1996; 34: 827-828 [PMID: 9082663]